Efficacy and Safety of Antithrombotic Therapy for Preventing and Treating Pediatric Thromboembolic Disease: a Systematic Review

Overview

Journal Sci Rep

Specialty Science

Date 2024 Jun 11

PMID 38862574

Authors

Hongjin Gao

Mingyu Chen

Youqi Huang

Huiting Liu

Yuze Lin

Min Chen

Affiliations

Soon will be listed here.

Abstract

This review used traditional and network meta-analyses (NMA) to conduct a comprehensive study of antithrombotic therapies in children with thromboembolic disease. We searched the PubMed, Embase, Cochrane Library, Web of Science and ClinicalTrials.gov databases from their inception to 26 February, 2023. And we finally included 16 randomized controlled trials. In the prevention of thromboembolic events (TEs), the use of anticoagulants had a low risk of TEs (relative risk (RR) 0.73, 95% CI 0.56 to 0.94) and a high risk of minor bleeding (RR 1.43, 95% CI 1.09 to 1.86) compared with no anticoagulants. In the treatment of TEs, direct oral anticoagulants (DOACs) were not inferior to standard anticoagulation in terms of efficacy and safety outcomes. In NMA, rivaroxaban and apixaban showed the lowest risk for TEs and major or clinically relevant nonmajor bleeding. According to the overall assessment of efficacy and safety, dabigatran may be the best choice for children with thromboembolic disease. The results of our study will provide references and suggestions for clinical drug selection.

References

Li A, Garcia D, Lyman G, Carrier M . Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res. 2018; 173:158-163. PMC: 6119655. DOI: 10.1016/j.thromres.2018.02.144. View

Pessotti C, Jatene M, Jatene I, Oliveira P, Succi F, Moreira V . Comparative trial of the use of antiplatelet and oral anticoagulant in thrombosis prophylaxis in patients undergoing total cavopulmonary operation with extracardiac conduit: echocardiographic, tomographic, scintigraphic, clinical and laboratory.... Rev Bras Cir Cardiovasc. 2015; 29(4):595-605. PMC: 4408824. DOI: 10.5935/1678-9741.20140111. View

Kahan B, Harhay M . Many multicenter trials had few events per center, requiring analysis via random-effects models or GEEs. J Clin Epidemiol. 2015; 68(12):1504-11. PMC: 4845666. DOI: 10.1016/j.jclinepi.2015.03.016. View

Hutton B, Salanti G, Caldwell D, Chaimani A, Schmid C, Cameron C . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015; 162(11):777-84. DOI: 10.7326/M14-2385. View

Ruud E, Holmstrom H, de Lange C, Hogstad E, Wesenberg F . Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies--a randomized, controlled study. Acta Paediatr. 2006; 95(9):1053-9. DOI: 10.1080/08035250600729092. View

Monagle P, Cuello C, Augustine C, Bonduel M, Brandao L, Capman T . American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv. 2018; 2(22):3292-3316. PMC: 6258911. DOI: 10.1182/bloodadvances.2018024786. View

Albisetti M, Andrew M . Low molecular weight heparin in children. Eur J Pediatr. 2002; 161(2):71-7. DOI: 10.1007/s00431-001-0873-9. View

Connor P, Sanchez van Kammen M, Lensing A, Chalmers E, Kallay K, Hege K . Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Adv. 2020; 4(24):6250-6258. PMC: 7756994. DOI: 10.1182/bloodadvances.2020003244. View

McCrindle B, Michelson A, Van Bergen A, Suzana Horowitz E, Sandoval J, Justino H . Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. J Am Heart Assoc. 2021; 10(22):e021765. PMC: 8751951. DOI: 10.1161/JAHA.120.021765. View

10.

Palumbo J, Lensing A, Brandao L, Hooimeijer H, Kenet G, van Ommen H . Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr. Blood Adv. 2022; 6(22):5821-5828. PMC: 9641171. DOI: 10.1182/bloodadvances.2022008160. View

11.

Jaffray J, Young G . Direct oral anticoagulants for use in paediatrics. Lancet Child Adolesc Health. 2022; 6(3):207-214. DOI: 10.1016/S2352-4642(21)00343-6. View

12.

Chan A, deVeber G, Monagle P, Brooker L, Massicotte P . Venous thrombosis in children. J Thromb Haemost. 2003; 1(7):1443-55. DOI: 10.1046/j.1538-7836.2003.00308.x. View

13.

Portman M, Jacobs J, Newburger J, Berger F, Grosso M, Duggal A . Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease. J Am Coll Cardiol. 2022; 80(24):2301-2310. DOI: 10.1016/j.jacc.2022.09.031. View

14.

Monagle P, Cochrane A, Roberts R, Manlhiot C, Weintraub R, Szechtman B . A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. J Am Coll Cardiol. 2011; 58(6):645-51. DOI: 10.1016/j.jacc.2011.01.061. View

15.

Mills E, Thorlund K, Ioannidis J . Demystifying trial networks and network meta-analysis. BMJ. 2013; 346:f2914. DOI: 10.1136/bmj.f2914. View

16.

Faustino E, Shabanova V, Raffini L, Kandil S, Li S, Pinto M . Efficacy of Early Prophylaxis Against Catheter-Associated Thrombosis in Critically Ill Children: A Bayesian Phase 2b Randomized Clinical Trial. Crit Care Med. 2020; 49(3):e235-e246. PMC: 7902342. DOI: 10.1097/CCM.0000000000004784. View

17.

Greiner J, Schrappe M, Claviez A, Zimmermann M, Niemeyer C, Kolb R . THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica. 2018; 104(4):756-765. PMC: 6442986. DOI: 10.3324/haematol.2018.194175. View

18.

Halton J, Brandao L, Luciani M, Bomgaars L, Chalmers E, Mitchell L . Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 2020; 8(1):e22-e33. DOI: 10.1016/S2352-3026(20)30368-9. View

19.

Spineli L . A Revised Framework to Evaluate the Consistency Assumption Globally in a Network of Interventions. Med Decis Making. 2021; 42(5):637-648. PMC: 9189723. DOI: 10.1177/0272989X211068005. View

20.

Chen J, Lv M, Jiang S, Wu S, Xu W, Qian J . Risk of nonmajor bleeding upon use of direct oral anticoagulants for preventing and treating venous thromboembolism: A network meta-analysis. Vasc Med. 2022; 27(6):565-573. DOI: 10.1177/1358863X221115213. View